Home > Financial Ratios > MANKIND PHARMA

MANKIND PHARMA
EV/Core EBITDA

    Back to All Ratios
MANKIND PHARMA is part of below Screeners ↓
Top Large Cap Stocks with Best Fundamentals
AD     Remove this Ad

MANKIND PHARMA Last 5 Year EV/Core EBITDA History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   EV/Core EBITDA(x) 30.2832.74-0.120.23-0.23

What is the latest EV/Core EBITDA ratio of MANKIND PHARMA ?

The latest EV/Core EBITDA ratio of MANKIND PHARMA is 30.28 based on Mar2025 Consolidated results.
Year EV/Core EBITDA
Mar202530.28
Mar202432.74
Mar2023-0.12
Mar20220.23
Mar2021-0.23

How is EV/Core EBITDA of MANKIND PHARMA Trending?

Years EV/Core EBITDA % Change
Mar2025 30.28
-7.51
Mar2024 32.74
Positive
Mar2023 -0.12
Negative
Mar2022 0.23
Positive
Mar2021 -0.23 -

Other Financial Ratios of MANKIND PHARMA


Compare EV/Core EBITDA ratio of peers of MANKIND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
MANKIND PHARMA ₹83,686.9 Cr -1.1% -3% -16.9% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹413,753.0 Cr 0.9% 6.2% -1.3% Stock Analytics
DIVIS LABORATORIES ₹167,032.0 Cr 2% 4.8% 4.6% Stock Analytics
TORRENT PHARMACEUTICALS ₹143,426.0 Cr 3.6% 6% 36.9% Stock Analytics
CIPLA ₹108,360.0 Cr -0.1% -3% -8.4% Stock Analytics
DR REDDYS LABORATORIES ₹106,859.0 Cr 1% 10.8% 4.7% Stock Analytics


MANKIND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
MANKIND PHARMA

-1.1%

-3%

-16.9%

SENSEX

0.2%

1.1%

8.8%


You may also like the below Video Courses